These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 6406468)

  • 1. Studies of bupropion's mechanism of antidepressant activity.
    Ferris RM; Cooper BR; Maxwell RA
    J Clin Psychiatry; 1983 May; 44(5 Pt 2):74-8. PubMed ID: 6406468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurochemical and neuropharmacological investigations into the mechanisms of action of bupropion . HCl--a new atypical antidepressant agent.
    Ferris RM; Maxwell RA; Cooper BR; Soroko FE
    Adv Biochem Psychopharmacol; 1982; 31():277-86. PubMed ID: 6282058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bupropion: a review of its mechanism of antidepressant activity.
    Ascher JA; Cole JO; Colin JN; Feighner JP; Ferris RM; Fibiger HC; Golden RN; Martin P; Potter WZ; Richelson E
    J Clin Psychiatry; 1995 Sep; 56(9):395-401. PubMed ID: 7665537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mode of action of antidepressant drugs.
    Sulser F
    J Clin Psychiatry; 1983 May; 44(5 Pt 2):14-20. PubMed ID: 6406444
    [No Abstract]   [Full Text] [Related]  

  • 5. Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo.
    Cooper BR; Hester TJ; Maxwell RA
    J Pharmacol Exp Ther; 1980 Oct; 215(1):127-34. PubMed ID: 6778989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the mechanism of antidepressant-like action of berberine chloride.
    Kulkarni SK; Dhir A
    Eur J Pharmacol; 2008 Jul; 589(1-3):163-72. PubMed ID: 18585703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor.
    Dhir A; Kulkarni SK
    Eur J Pharmacol; 2007 Jul; 568(1-3):177-85. PubMed ID: 17509558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of the antidepressant activity of the enantiomers of bupropion.
    Musso DL; Mehta NB; Soroko FE; Ferris RM; Hollingsworth EB; Kenney BT
    Chirality; 1993; 5(7):495-500. PubMed ID: 8240925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Animal models used in prediction of antidepressant effects in man.
    Cooper BR; Howard JL; Soroko FE
    J Clin Psychiatry; 1983 May; 44(5 Pt 2):63-6. PubMed ID: 6406466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical evaluation of McN-5707 as a potential antidepressant.
    Shank RP; Gardocki JF; Schneider CR; Vaught JL; Setler PE; Maryanoff BE; McComsey DF
    J Pharmacol Exp Ther; 1987 Jul; 242(1):74-84. PubMed ID: 3039115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bupropion: a new antidepressant drug, the mechanism of action of which is not associated with down-regulation of postsynaptic beta-adrenergic, serotonergic (5-HT2), alpha 2-adrenergic, imipramine and dopaminergic receptors in brain.
    Ferris RM; Beaman OJ
    Neuropharmacology; 1983 Nov; 22(11):1257-67. PubMed ID: 6320035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of bupropion.
    Bryant SG; Guernsey BG; Ingrim NB
    Clin Pharm; 1983; 2(6):525-37. PubMed ID: 6140095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Correlation of presynaptic components (uptake--release) in antidepressants].
    Dolzhenko AT
    Farmakol Toksikol; 1984; 47(5):22-5. PubMed ID: 6094236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic profile of fezolamine fumarate: a nontricyclic antidepressant in animal models.
    Baizman ER; Ezrin AM; Ferrari RA; Luttinger D
    J Pharmacol Exp Ther; 1987 Oct; 243(1):40-54. PubMed ID: 3668867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacologic basis for therapeutic interest in bupropion.
    Soroko FE; Maxwell RA
    J Clin Psychiatry; 1983 May; 44(5 Pt 2):67-73. PubMed ID: 6406467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.
    Millan MJ; Newman-Tancredi A; Rivet JM; Brocco M; Lacroix P; Audinot V; Cistarelli L; Gobert A
    J Pharmacol Exp Ther; 1997 Jul; 282(1):132-47. PubMed ID: 9223549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central pre- and postsynaptic 5-HT1A receptors in rats treated chronically with a novel antidepressant, cericlamine.
    Jolas T; Haj-Dahmane S; Kidd EJ; Langlois X; Lanfumey L; Fattaccini CM; Vantalon V; Laporte AM; Adrien J; Gozlan H
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1432-43. PubMed ID: 8138956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is dopamine a limiting factor of the antidepressant-like effect in the mouse forced swimming test?
    Renard CE; Dailly E; Nic Dhonnchadha BA; Hascoet M; Bourin M
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1255-9. PubMed ID: 15588751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between bupropion disposition and dopamine uptake inhibition in rats and mice.
    Butz RF; Welch RM; Findlay JW
    J Pharmacol Exp Ther; 1982 Jun; 221(3):676-85. PubMed ID: 6806465
    [No Abstract]   [Full Text] [Related]  

  • 20. Central effects of repeated treatment with bupropion.
    Klimek V; Nowak G; Czyrak A
    Pol J Pharmacol Pharm; 1985; 37(3):243-52. PubMed ID: 3934652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.